Clinical Trials Sponsored by BioSCIENCE GmbH

Total 5041 results

Biofrontera Bioscience GmbH

Recruiting

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Actinic Keratoses

United States
Biofrontera Bioscience GmbH

Completed

Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)

Actinic Keratosis

Germany
BioSCIENCE GmbH
HeiMed

Completed

Safety and Efficacy of the HA-based Dermal Fillers HYAPROF® SOFT and HYAPROF® BALANCE (PMCF_HYAPROF)

Dermal Filler

Germany
BioSCIENCE GmbH
HeiMed

Completed

Safety and Efficacy of the HA-based Dermal Fillers HYAcorp Lips and Face (PMCF_HYAcorp)

Dermal Filler

Germany
Biofrontera Bioscience GmbH

Completed

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Actinic Keratoses

United States
Biofrontera Bioscience GmbH
Accovion GmbH

Completed

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Basal Cell Carcinoma (BCC)

Germany
Biofrontera Bioscience GmbH

Recruiting

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Acne Vulgaris

United States
Biofrontera Bioscience GmbH

Active, not recruiting

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Superficial Basal Cell Carcinoma

United States
Biofrontera Bioscience GmbH

Completed

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Keratosis | Actinic Keratosis | Keratosis, Actinic

United States
Themis Bioscience GmbH

Completed

Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)

Zika Virus

Austria
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
Themis Bioscience GmbH

Completed

Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

Chikungunya Virus Infection

United Kingdom
Biofrontera Bioscience GmbH

Completed

Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.

Actinic Keratosis
Biofrontera Bioscience GmbH
Accovion GmbH

Completed

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Actinic Keratosis
Themis Bioscience GmbH

Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) (MV-ZIKA-RSP)

Zika Virus Infection

Austria
Biofrontera Bioscience GmbH

Completed

A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis

Actinic Keratosis
Lophius Biosciences GmbH

Completed

Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients (CMValue)

Kidney Transplantation | Cytomegalovirus | CMV Specific Immune Response

Germany
Lophius Biosciences GmbH

Completed

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Renal Failure Chronic Requiring Dialysis
Sygnis Bioscience GmbH & Co KG

Completed

AXIS 2: AX200 for the Treatment of Ischemic Stroke (AXIS-2)

Acute Ischemic Stroke

Spain, Belgium, Germany, Slovakia, Austria, Czech Republic, Poland
UCB BIOSCIENCES GmbH

Completed

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy (BRIGHT)

Idiopathic Parkinson's Disease

United States, Austria, Hungary, Poland, Slovakia, Slovenia, Spain
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

Healthy

Germany
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects

Healthy | Renal Impairment

Germany
UCB BIOSCIENCES GmbH

Completed

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

Axial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpA

United States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

Spondyloarthropathies

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Italy, Mexico, Poland, Spain, United Kingdom, Netherlands
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain (DOLORES)

Advanced Idiopathic Parkinson's Disease

United States, Germany, Poland, Slovakia
UCB BIOSCIENCES GmbH

Completed

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome (ENCORE)

Restless Legs Syndrome

Germany
UCB BIOSCIENCES GmbH

Completed

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Restless Legs Syndrome | End-Stage Renal Disease

United States, Austria, Finland, France, Germany, Italy
UCB BIOSCIENCES GmbH

Withdrawn

A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

Crohn's Disease
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Not yet recruiting

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Advanced Solid Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Withdrawn

JS001+IMP4297 in Patients With Advanced Cancer

Advanced Cancer
UCB BIOSCIENCES GmbH
PPD

Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Crohn Disease

Russian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA

Non-radiographic Axial Spondyloarthritis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Active Ankylosing Spondylitis

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Active, not recruiting

A Pharmacokinetic Study of JS002 in Healthy Subjects

Health Volunteer

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Study of WJ05129 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Subjects With Liver Function Injury | Normal Liver Function Subject

China
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
GWT-TUD GmbH
Incyte Biosciences International Sàrl

Terminated

Study in Patients With Chronic Leukemia (PONS)

Leukemia, Myeloid, Chronic-Phase

Germany
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older (SP0993)

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spa... and more
UCB BIOSCIENCES GmbH
Eden Sarl

Completed

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

Epilepsy | Monotherapy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Swede... and more
UCB BIOSCIENCES GmbH
Schwarz BioSciences GmbH; Alfred-Nobel-Str. 10; 40789 Monheim am Rhein

Completed

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Healthy

Germany

Clinical Trials Sponsored by BioSCIENCE GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations